DC01D165-E257-49D6-8B9B-37CA7DE398F6
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 5.946123521681997
- age_years
- 50
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.548
- MYC_TARGETS_V1+0.537
- PROTEIN_SECRETION+0.522
- MTORC1_SIGNALING+0.497
- G2M_CHECKPOINT+0.489
- NOTCH_SIGNALING+0.469
- TGF_BETA_SIGNALING+0.466
- ANGIOGENESIS+0.443
- DNA_REPAIR+0.434
- TNFA_SIGNALING_VIA_NFKB+0.418
Top 10 suppressed
- KRAS_SIGNALING_DN-0.450
- SPERMATOGENESIS-0.271
- PANCREAS_BETA_CELLS-0.242
- MYOGENESIS-0.200
- APICAL_SURFACE-0.082
- ESTROGEN_RESPONSE_LATE-0.080
- ESTROGEN_RESPONSE_EARLY-0.030
- BILE_ACID_METABOLISM-0.018
- XENOBIOTIC_METABOLISM+0.100
- HEME_METABOLISM+0.105
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 0E66EFB0-712B-4A52-8F75-A37F030CABEF | — | — | 0.977 |
| 2 | 1A9B5D3A-CEB0-4225-9C3D-CBE98A007A3A | — | — | 0.976 |
| 3 | 65F93AB7-AA99-49B5-8D59-7D0DE9CA9E34 | — | — | 0.976 |
| 4 | 7876A884-F031-42AB-ADC0-89589760FB6B | — | — | 0.973 |
| 5 | 9BFF7746-9003-4941-9590-0B813E00B326 | — | — | 0.972 |
| 6 | 66FF1C46-83F0-4EEC-9871-448C8C7EA3AE | — | — | 0.971 |
| 7 | 30D8578D-0B48-4D03-9E39-6425494ECD5C | — | — | 0.968 |
| 8 | DD203D19-D635-4112-AF75-9724E0A64A0B | — | — | 0.967 |
| 9 | 825AC0F8-4D16-4109-AA6A-4648934E3C35 | — | — | 0.966 |
| 10 | 8730AABF-0720-4754-82B0-722150A485B8 | — | — | 0.966 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.548 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.537 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.522 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.497 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.489 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.469 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.466 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.443 | Remibrutinib | — uncovered |
| DNA_REPAIR | 0.434 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.418 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.417 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.416 | Inavolisib | — uncovered |
| APOPTOSIS | 0.408 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.403 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.390 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.372 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.362 | Idelalisib | — uncovered |
| COMPLEMENT | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.357 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.348 | Idelalisib | — uncovered |